The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study
Patients with EMD who had ≥ 2 HRA experienced an extremely poor prognosis, which could not be improved by single transplantation or CD38 monoclonal antibody-based treatment. The number of HRA could serve as an important factor in guiding treatment choices and predicting prognosis in patients with EMD. Furthermore, 1q21 + remained a significant factor associated with worse survival outcomes in EMD.
Authors
- Xiaowei Nie (ORCID: https://orcid.org/0000-0003-2443-0569)
- Weiling Xu (ORCID: https://orcid.org/0000-0003-1572-4311)
- Demei Feng (ORCID: https://orcid.org/0009-0004-7038-3673)
- Fengyan Jin (ORCID: https://orcid.org/0000-0003-2288-556X)
- Yuan Feng (ORCID: https://orcid.org/0000-0002-4650-2685)
- Dong Liang (ORCID: https://orcid.org/0009-0008-8862-223X)
- Yurong Yan
- Yang Liang (ORCID: https://orcid.org/0000-0002-5507-4133)
- Shenrui Bai (ORCID: https://orcid.org/0000-0002-2804-6292)
- Zhongjun Xia
- Qiao-Li Wang (ORCID: https://orcid.org/0000-0003-4152-7821)
- Hua Wang (ORCID: https://orcid.org/0000-0002-9751-8847)
- Min Zeng (ORCID: https://orcid.org/0009-0002-4575-0430)
- Xiaoqin Chen (ORCID: https://orcid.org/0000-0003-0491-5753)
Institutions
- Sun Yat-sen University (CN)
- Jilin University (CN)
- First Hospital of Jilin University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s12885-024-13309-z
- Citations
- 3
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.36